Drivers of Eosinophilic COPD Exacerbations — DICE  

COPD Exacerbation Clinical Trial

Official title: Drivers of Eosinophilic COPD Exacerbations

Status Recruiting

Clinical Trial Summary

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes.

Clinical Trial Description

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes to better understand why some patients are more at risk for eosinophilic COPD exacerbations. Secondary objectives:

1. Investigate differences in microbiome composition and immunophenotyping profiles in peripheral blood per subtype.

2. Assess for clinical differences between all COPD exacerbation subtypes.

3. Assess if and how baseline meta-transcriptomics either in nasal epithelium or sputum and blood immunophenotyping can be utilized to predict COPD exacerbation subtype.

4. Determine if the microbiome in sputum and nasal epithelial material are comparable.

5. Determine if different subtypes of COPD exacerbations respond differently to standard treatment with oral prednisolone (40 mg daily) with or without antibiotics.

6. To evaluate if metabolic responses during recovery are different in patients with increased systemic inflammation compared to patients without systemic inflammation at exacerbation ;

Related Conditions & MeSH terms

• COPD Exacerbation
• Eosinophilia
• Pulmonary Disease, Chronic Obstructive

• NCT number: NCT04961060
• Study type: Observational
• Source: University Medical Center Groningen
• Contact: Lisa H van Smoorenburg, MSc.
• Phone: +3150 361 6102
• Email: l.h.van.smoorenburg@umcg.nl
• Status: Recruiting
• Start date: July 2021
• Completion date: January 2025